key: cord-0846393-nq0qe8qf
authors: nan
title: Mismatched Double-Stranded RNA: PolyI:PolyC12U
date: 2012-11-27
journal: Drugs R D
DOI: 10.2165/00126839-200405050-00006
sha: 2e6a61c794973c2754d20968b7a3d2f06789ad63
doc_id: 846393
cord_uid: nq0qe8qf

Ampligen® [polyI:polyC12U] is a mismatched double-stranded RNA that acts by inducing interferon production (immunomodulator) and by activating an intracellular enzyme (RNase-L) against viral RNA transcripts (antiviral). Ampligen®, currently under development by Hemispherx Biopharma in the US, acts on the immunological system through T-lymphocyte stimulation and is indicated for the treatment of chronic fatigue syndrome and acquired immunodeficiency deficiency syndrome (AIDS), as part of the combined therapy. Ampligen® is available for licensing worldwide. In February 2004, Fujisawa Deutschland GmbH, a subsidiary of Fujisawa Pharmaceutical Co., entered into an option agreement with Hemispherx Biopharma with the intent of becoming a distributor for Ampligen® for the potential treatment of chronic fatigue syndrome in Germany, Switzerland and Austria. An option fee of €400 000 was paid pursuant to the terms of the option agreement and upon execution of the Distribution Agreement, Fujisawa will pay Hemispherx fees and milestone payments with a potential worth of several millions of dollars.[1] In September 2003, Hemispherx Biopharma Inc. entered into an agreement with Guangdong Medicine Group Corporation to organise clinical trials, marketing, sales and distribution for both of its lead compounds, Ampligen® and Alferon N® in the People’s Republic of China. The agreement stipulates that the Guangdong Medicine Group Corporation (GMC) will conduct clinical trials with Ampligen® for the treatment of HIV. All costs related to the trials are to be covered by GMC. Additionally, GMC has to develop and implement marketing and promotional programmes.[2] In May 2003, Hemispherx Biopharma and the Center for Cell and Gene Therapy entered into a research project agreement that will see Ampligen® implemented in a protocol used in patients with relapsed EBV-positive Hodgkin’s Lymphoma.[3] In March 2002, Esteve and Hemispherx Biopharma entered into a collaborative agreement under which Esteve will be the sole distributor of Ampligen® in Spain, Portugal and Andorra for the treatment of chronic fatigue syndrome. Under this agreement, in addition to other terms, Esteve will also collaborate in the drug product development by conducting clinical studies in Spain in patients coinfected with HIV/HCV. In July 2001 Hemispherx Biopharma announced that it had formed a strategic alliance with Empire Health Resources for clinical trials of Ampligen® in the treatment of HIV and hepatitis C virus infections. Empire Health Resources, a healthcare management firm, will be responsible for accrual and retention of patients for HIV trials, and protocols for trials in patients with hepatitis C or both HIV and hepatitis C infections. Hemispherx has entered into a collaboration with RED Laboratories, and RED Laboratories NV expects that this will facilitate the continued development of Ampligen®. Hemispherx has also entered into an agreement with Schering Plough to use a Schering facility as its principal manufacturing platform in the US. This agreement may be expanded to include other territories. Hemispherx and AOP Orphan Pharmaceuticals have signed a marketing agreement for Ampligen® for the treatment of chronic fatigue syndrome for Austria, the Czech Republic, Poland and Hungary. In an arrangement between Hemispherx and Bioclones, Bioclones has certain marketing rights for Ampligen® in the Southern Hemisphere, UK and Ireland. In the US, Ampligen® has been granted orphan drug status for the treatment of AIDS, renal cell carcinoma (phase II, completed), chronic fatigue syndrome (phase III) and invasive/metastatic malignant melanoma (phase II). In August 2004, Hemispherx announced that it intends to use the proceeds from the private placement of company stock to complete the clinical work for its immunotherapeutics/ antivirals Ampligen® and Oragens™. Previously, Hemispherx submitted an application to the EMEA for the approval of Ampligen® for the treatment of chronic fatigue syndrome; the first stage of the regulatory review has been cleared. In 2000, Hemispherx Europe (Hemispherx) obtained orphan drug status for Ampligen® for the treatment of chronic fatigue syndrome in the EU, providing Hemispherx with 10 years of marketing exclusivity following the launch of the drug, as well as potential financial research benefits for the agent. In February 2000, Crystaal Corporation (now Biovail Pharmaceuticals Canada) acquired exclusive marketing rights to Ampligen® in Canada, where it submitted an NDA for the agent for the treatment of chronic fatigue syndrome. In the meantime, Ampligen® has been available since May 1996 under the Canadian Emergency Drug Release Programme for the treatment of chronic fatigue syndrome and immune dysfunction syndrome by Rivex Pharma (Helix BioPharma). Bioclones has initiated clinical studies with Ampligen® for the treatment of chronic fatigue syndrome in Australia. The active substance for Ampligen® is manufactured by F.H. Faulding Ltd. Clinical treatment programmes for chronic fatigue syndrome in other Pacific Rim countries are planned. Ampligen® is available for severe chronic fatigue syndrome on a named patient, cost-recovery basis in South Africa. Hemispherx has developed a ‘ready-to-use’ liquid formulation of the drug and has begun treating patients with chronic fatigue syndrome in ongoing clinical trials. Hemispherx has also developed an oral version of the drug (Oragen®), which is undergoing preclinical evaluation. In February 2001, Hemispherx Biopharma announced that it was initiating phase II/III trials of Ampligen® in the treatment of late-stage, multidrug-resistant strains of HIV in the European Union. Patients treated in these studies will have exhausted all other treatment options. In July 2001, Hemispherx stated that Ampligen® was being evaluated in a phase IIb trial in patients with HIV in the US. The trial, comprising two studies, REARMI and REARMII (Research/Evaluation of Ampligen® for Retroviral Mutations I and II), will evaluate the ability of Ampligen® to prevent the emergence of mutated, drug-resistant strains of the virus. ‘Several hundred’ patients currently on antiretroviral therapy and at risk of viral relapse will be enrolled at centres in Connecticut, New York, Florida and California. A second phase IIb study evaluating the effect of Ampligen® on structured treatment interruptions (STI) is also underway. Final results from this study were reported in December 2002. NIH sponsored studies of potential therapies for SARS have identified Ampligen® as having unusually high and consistent antiviral activity against human coronavirus, the pathogen implicated as the causative agent of the disease. Ampligen® demonstrated very high potency at very low concentrations (0.4 μg/mL) and had a favourable safety profile.[4] In October 2003, Hemispherx announced that, based on these promsing new results, the company will stockpile injectible and/or oral formats of Ampligen® and Alferon N®.[5] Independent researchers have demonstrated the antiviral activity of Ampligen® against flaviviruses (West Nile virus, Equine Encephalitis virus, Dengue fever virus and Japanese Encephalitis virus) as well as virus classes associated with bioterrorism. In an animal study, Ampligen® was shown to prevent destruction of nerve cells, reduce virus concentrations in the brain and blood stream and increase survival rates.[6] Researchers at the Rega Institute in Belgium have published results from an animal study demonstrating that Ampligen® was superior at protecting mice against coxsackie B3 virus-induced myocarditis compared with pegylated interferon.[7] In May 2004 Hemispherx announced that it had filed an expanded US patent application covering the use of Ampligen® for the potential treatment and prevention of severe acute respiratory syndrome (SARS) and dreaded emerging viruses.

Hemispherx has entered into a collaboration with RED Laboratories, and RED Laboratories NV expects that this will facilitate the continued development of Ampligen ® . Hemispherx has also entered into an agreement with Schering Plough to use a Schering facility as its principal manufacturing platform in the US. This agreement may be expanded to include other territories.

Hemispherx and AOP Orphan Pharmaceuticals have signed a marketing agreement for Ampligen ® for the treatment of chronic fatigue syndrome for Austria, the Czech Republic, Poland and Hungary.

In an arrangement between Hemispherx and Bioclones, Bioclones has certain marketing rights for Ampligen ® in the Southern Hemisphere, UK and Ireland.

In the US, Ampligen ® has been granted orphan drug status for the treatment of AIDS, renal cell carcinoma (phase II, completed), chronic fatigue syndrome (phase III) and invasive/metastatic malignant melanoma (phase II).

In August 2004, Hemispherx announced that it intends to use the proceeds from the private placement of company stock to complete the clinical work for its immunotherapeutics/ antivirals Ampligen ® and Oragens™.

Previously, Hemispherx submitted an application to the EMEA for the approval of Ampligen ® for the treatment of chronic fatigue syndrome; the first stage of the regulatory review has been cleared. In 2000, Hemispherx Europe (Hemispherx) obtained orphan drug status for Ampligen ® for the treatment of chronic fatigue syndrome in the EU, providing Hemispherx with 10 years of marketing exclusivity following the launch of the drug, as well as potential financial research benefits for the agent.

In February 2000, Crystaal Corporation (now Biovail Pharmaceuticals Canada) acquired exclusive marketing rights to Ampligen ® in Canada, where it submitted an NDA for the agent for the treatment of chronic fatigue syndrome. In the meantime, Ampligen ® has been available since May 1996 under the Canadian Emergency Drug Release Programme for the treatment of chronic fatigue syndrome and immune dysfunction syndrome by Rivex Pharma (Helix BioPharma).

Bioclones has initiated clinical studies with Ampligen ® for the treatment of chronic fatigue syndrome in Australia. The active substance for Ampligen ® is manufactured by F.H. Faulding Ltd. Clinical treatment programmes for chronic fatigue syndrome in other Pacific Rim countries are planned. Ampligen ® is available for severe chronic fatigue syndrome on a named patient, cost-recovery basis in South Africa.

Hemispherx has developed a 'ready-to-use' liquid formulation of the drug and has begun treating patients with chronic fatigue syndrome in ongoing clinical trials. Hemispherx has also developed an oral version of the drug (Oragen ® ), which is undergoing preclinical evaluation.

In February 2001, Hemispherx Biopharma announced that it was initiating phase II/III trials of Ampligen ® in the treatment of late-stage, multidrug-resistant strains of HIV in the European Union. Patients treated in these studies will have exhausted all other treatment options.

In July 2001, Hemispherx stated that Ampligen ® was being evaluated in a phase IIb trial in patients with HIV in the US. The trial, comprising two studies, REARMI and REARMII (Research/Evaluation of Ampligen ® for Retroviral Mutations I and II), will evaluate the ability of Ampligen ® to prevent the emergence of mutated, drug-resistant strains of the virus. 'Several hundred' patients currently on antiretroviral therapy and at risk of viral relapse will be enrolled at centres in Connecticut, New York, Florida and California. A second phase IIb study evaluating the effect of Ampligen ® on structured treatment interruptions (STI) is also underway. Final results from this study were reported in December 2002.

NIH sponsored studies of potential therapies for SARS have identified Ampligen ® as having unusually high and consistent antiviral activity against human coronavirus, the pathogen implicated as the causative agent of the disease. Ampligen ® demonstrated very high potency at very low concentrations (0.4 μg/ mL) and had a favourable safety profile. [4] In October 2003, Hemispherx announced that, based on these promsing new results, the company will stockpile injectible and/or oral formats of Ampligen ® and Alferon N ® . [5] Independent researchers have demonstrated the antiviral activity of Ampligen ® against flaviviruses (West Nile virus, Equine Encephalitis virus, Dengue fever virus and Japanese Encephalitis virus) as well as virus classes associated with bioterrorism. In an animal study, Ampligen ® was shown to prevent destruction of nerve cells, reduce virus concentrations in the brain and blood stream and increase survival rates. [6] Researchers at the Rega Institute in Belgium have published results from an animal study demonstrating that Ampligen ® was superior at protecting mice against coxsackie B3 virus-induced myocarditis compared with pegylated interferon. [7] In May 2004 Hemispherx announced that it had filed an expanded US patent application covering the use of Ampligen ® for the potential treatment and prevention of severe acute respiratory syndrome (SARS) and dreaded emerging viruses.

During combination therapy with zidovudine and Ampligen ® , toxicity was similar to that caused by zidovudine alone. [11] 

In a study that compared Ampligen ® with placebo in zidovudine recipients, the total number of During clinical trials in which HIV-infected paadverse events did not differ significantly between tients received IV infusions of mismatched doubletreatment groups. [12] stranded RNA at dose levels of 10-570 mg/m 2 /dose, In HIV-1-positive patients undergoing structured the most frequent adverse events were flushing, treatment interruptions (STI) of HAART, adverse chills, fever, tight chest, dyspnoea, 'flu-like sympevents associated with Ampligen ® were mild and toms and nausea. All reactions were self-limiting self-limiting. There was no incidence of insulin reand generally subsided after the infusion was comsistance, hyperlipidaemia, or adverse changes in pleted. Infusions were usually accompanied by tranlactic acid levels. [13] sient leucopenia and then leucocytosis. One patient who received mismatched double-stranded RNA

The most common adverse events in a clinical 570 mg/m 2 discontinued therapy after developing trial with metastatic melanoma patients included 'flu-like symptoms and fatigue. [8] [9] [10] myalgia, headache and fatigue. [14] compared with those of placebo in a randomised, double-blind, crossover study (ACTG 056) in vol-Mismatched double-stranded RNA is synergistic unteers. Overall, there were no significant differwith multiple anti-HIV drugs. Combination indices ences between the two treatments in terms of prowere determined for 14 anti-HIV agents alone and in duction of interferon and biological markers of incombination with mismatched double-stranded terferon, T lymphocytic function, lymphocyte RNA using dose-effect analyses and the CalcuSyn proliferative responses and natural killer cell activifor Windows software. Mismatched double-strandty. Symptom scores were greater in mismatched ed RNA was synergistic in combination with abadouble-stranded RNA recipients than in placebo cavir, zidovudine, zalcitabine, didanosine, sta-vurecipients, but symptoms were mild in nature and dine, efavirenz, indinavir, ritonavir, nelfinavir and the between-group difference was only significant amprenavir. It was synergistic to antagonistic with on the day after dosing. [10] lamivudine, delavirdine, nevirapine and sa-In 15 patients with chronic fatigue syndrome, quinavir. [15] Ampligen ® normalised the upregulated 2-5A synthetase/RNase L system and cleared human 1.3 Pharmacodynamics herpesvirus 6 antigen-positive cells from peripheral blood mononuclear cell cultures. [17] 

Preclinical studies: Ampligen ® reduced serum Mismatched double-stranded tion returned to baseline levels after treatment dis-RNA induces expression of the physiologically continuation. [16] functioning antiviral protection system (2-5A Clinical studies: The effects of mismatched synthetase/RNase L system) in cells. In vitro, Amdouble-stranded RNA on immune function were pligen ® 9.7 μg/mL inhibited the HIV-related reduc-tion of Molt-3 cell growth rate by 50%. It acted tion ratios ranging from 100 : 1 to 1 : 50. [19] Amsynergistically with a reverse transcriptase inhibitor pligen ® also acted synergistically with zidovudine and with an antisense oligonucleotide directed against zidovudine-resistant strains. [11] against the tat gene. [18] The compound has been shown to inhibit human Ampligen ® did not display any synergism herpes virus-6 (HHV-6) infection in T lymphocytes against HIV in vitro when used in combination with at concentrations of 100 and 200 μg/mL, [20, 21] and is didanosine. In contrast, synergism was demonstrated between Ampligen ® and zidovudine at combina-also active against rotavirus. [22] Mismatched double-stranded RNA was equally provement of 43% (from 53 at baseline to 76). active against wild-type HIV and HIV resistant to Exercise performance was measured by bicycle testnevirapine, protease inhibitors and nucleoside re-ing; oxygen uptake improved from 1.16 L/min at verse trancriptase inhibitors. [15] baseline to 1.48 L/min after treatment with mismatched double-stranded RNA. The cognitive improvement seen in patients receiving mismatched 1.5 Therapeutic Trials double-stranded RNA was measured using the cognitive subscale of the SCL 90-R or neuropsychologi-

cal function tests. Significantly greater improve-Melanoma: Ten patients with metastatic melanoments were seen in patients receiving mismatched ma were treated with mismatched double-stranded double-stranded RNA compared with placebo. Mis-RNA in an open-label phase I/II trial. The drug was matched double-stranded RNA was generally well administered IV at low dose (80mg) to one patient, tolerated according to a media release (15/10/1996). and at high dose (200-1000mg) to nine patients, Of the patients treated with mismatched doubleover 30-60 minutes twice weekly for 3-111 weeks.

stranded RNA, about 80% experienced an apparent Two of the patients receiving high-dose therapy 'complete clinical recovery' after 6 months' treatachieved a complete response. Both received mainment; spontaneous improvement in untreated patenance therapy for at least 12 months following this tients with chronic fatigue syndrome is about and have remained in complete response without 2%. [26, 27] further therapy at 21 and 91 months. Mismatched double-stranded RNA was well tolerated. [14] 

Hepatitis B: Results of a phase I/II study of Chronic fatigue syndrome: Ampligen ® signifi-mismatched double-stranded RNA 400-600mg two cantly improved patients' physical performance as to three times/week in eight patients with chronic assessed by Treadmill Exercise Tolerance Testing hepatitis B indicated that the drug may have an (ETT) in a 40-week placebo-controlled phase III antiviral effect. Four patients lost HBV DNA and study in 234 patients with severely debilitating three patients became HBeAg seronegative during chronic fatigue syndrome. Ampligen 400mg twice 24 weeks' treatment. None of the patients have weekly was superior to placebo for improved ETT relapsed. [28] (19.4 vs 5.1%) for the patient population that com-Results from a phase I study (ACTG 038) were pleted 40 weeks' treatment and also for the intentunable to confirm previous beneficial effects of misto-treat population (17.7 vs 4.3%) that completed matched double-stranded RNA in HIV infection. <40 weeks treatment. [23, 24] Thirty-nine HIV-infected patients with asymptomat-In a randomised, placebo-controlled trial, Am-ic disease or early ARC received one of six doses of pligen ® therapy improved physical and cognitive mismatched double-stranded RNA for 9 or 25 performance in patients with chronic fatigue syn-weeks. Mismatched double-stranded RNA had no drome, a condition with a possible viral aetiolo-significant effects on p24 antigenaemia, HIV gy. [25] viraemia or the number of HIV-infected cells. However, the rate of CD4+ cell depletion was reduced; In a Belgium study, patients with chronic fatigue this effect was dose-dependent. In addition, no pasyndrome were randomised to receive mismatched tient developed an opportunistic infection or any double-stranded RNA [Ampligen ® ] (200-400mg other new HIV-associated symptoms while receivtwice weekly) or placebo for 24 weeks. Mismatched ing mismatched double-stranded RNA. [9] double-stranded RNA significantly improved cognitive and physical performance. Physical perform-In patients with at least 6 months of previous ance for activities of daily living, measured using zidovudine treatment, Ampligen ® therapy administhe Karnofsky Performance Score, showed an im-tered prior to the development of advanced stage symptoms was associated with higher CD4 counts In the second analysis, the median duration of STI in the Ampligen ® group was >18 weeks, compared and increased immune function compared with unwith 7 weeks in the concurrent control, non-Amtreated patients. Thus, Ampligen ® appears to have pligen ® group. [29] activity against zidovudine-resistant HIV strains.

In a phase IIb study (AMP 720) of patients with In a study conducted in 36 zidovudine-treated HIV undergoing up to three structured treatment patients, mismatched double-stranded RNA therapy interruptions (STI) of HAART, Ampligen ® (400mg was most effective when initiated earlier in the IV twice weekly) therapy resulted in significant course of HIV disease. Over a 48-week study periprolongation of controlled HIV viraemia, compared od, patients treated with Ampligen ® (400 or 700mg with untreated controls. Patients taken off HAART twice weekly) had a mean decrease in CD4+ count but given Ampligen ® (n = 7) continued to show of 52 cells/μL compared with 89 cells/μL in placebo virus levels <5000 copies/mL for a mean of 25 recipients. Ampligen ® -treated patients with baseline weeks and counting. In the control group, patients CD4+ counts ≥300 cells/μL showed a mean increase (n = 9) taken off HAART and not given Ampligen ® , in CD4+ count of 26 cells/μL, which peaked at week developed an HIV rebound within a mean of 13 24. Placebo recipients had a consistent decrease weeks. In addition, the Ampligen ® group demonfrom baseline. A change to Ampligen ® therapy after strated an increase in CD8+ cells, suggesting induc-48 weeks of placebo treatment reversed the CD4+ tion of immunogenicity. [13, 30, 31] decline in seven patients. Ampligen ® recipients were more likely to exhibit a delayed-type hypersensitivity response and less likely to progress to AIDS References than placebo recipients. [12] 

A phase I study

Poly(I):poly(C12U) of ampligen in human immunodeficiency virus-infected subinhibits in vitro replication of human herpesvirus type 6. jects

Biologic effects after a single dose of poly(I):poly(C12U) in healthy volunits human herpesvirus-6 in vitro

Effect of poly(I)

row progenitor cell elements

Available from double-blind placebo-controlled study of the double-stranded URL

A phase IIB prospective, ance with ampligen compared to placebo

Aids Conference Supplement: 37

A controlled clinical trial

Phase I/II study of poly with a specifically configured RNA drug, poly(I).poly(C12U), I:polyC(12)U (Ampligen ® ) shows activity against metastatic in chronic fatigue syndrome. Clinical Infectious Diseases 18 melanoma

anti-HIV drugs and is active against drug-sensitive and drug-27. Helix BioPharma Corporation. Belgium Clinical Trial Demonresistant HIV-1 in vitro

Ampligen treatment of chrontreatment of ducks congenitally-infected with duck hepatitis B ic hepatitis B

Upregulation poly C12U increases the control of HIV during strategic treatof the 2-5A synthetase/RNase L antiviral pathway associated ment interruption in chronically HIV infected patients. Media with chronic fatigue syndrome

A phase IIB prospective, human immunodeficiency viral (HIV-1) effect of the immurandomized, controlled study evaluating AMPLIGEN during nomodulator ampligen (mismatched double-stranded RNA) structured treatment interruption of HAART in HIV infection. with inhibitors of reverse transcriptase and HIV-1 regulatory

The effect of Structured Treatment Interruption in HIV at DART Confercombinations of ampligen and zidovudine or dideoxyinosine against human immunodeficiency viruses in vitro